|
Galcanezumab
|
DB14042 |
[LY2951742/galcanezumab is a fully humanized monoclonal antibody against human calcitonin gene-related peptide (CGRP) that is developed by ELi Lilly and Company.[A33105] This therapy is given as a single subcutaneous injection twice a month and ongoing clinical trials for the agent are for episodic and chronic migraine as well as cluster headaches.[A33114]
Although various small-molecule CGRP receptor antagonists have also been developed, humanized monoclonal antibodies like galcanezumab are specifically designed to potently and selectively bind to the CGRP entities directly.[A33112] Given this target specificity, lack of off-target toxicity, and characteristic proteolysis profile of immunoglobulin antibodies to not undergo metabolism by liver enzymes, galcanezumab possesses favourable and promising safety and tolerability.[A33112]
Galcanezumab was given FDA approval on 27 September 2018.[L4894]] |
|
Palmidrol
|
DB14043 |
[A cannabinoid receptor-inactive eCB-related molecule used as prophylactic in helping to prevent respiratory viral infection. Palmidrol is available for human use as a supplement (400 mg capsules) and as food for medical purposes In Italy and Spain (300 mg and 600 mg tablets).] |
|
Tozuleristide
|
DB15375 |
[Tozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).] |
|
Cobalt Co-60
|
DB15374 |
[Cobalt Co-60 is under investigation in clinical trial NCT02891083 (Adjuvant Therapies or Surgery Alone for High Risk pN0 Esophageal Cancer).] |
|
Hopantenic acid
|
DB14044 |
[Hopantenic acid (Pantogam) is a central nervous system depressant. Hopantenic acid has a unique spectrum of pharmacological effects (nootropic, anticonvulsant, mild activating) in the absence of addiction, hyperstimulation or withdrawal syndrome. [A33115]] |
|
MK-2748
|
DB15371 |
[MK-2748 is under investigation in clinical trial NCT01593735 (A Multiple Dose Study to Evaluate the Safety and Efficacy of MK-2748 in Hepatitis C-Infected Participants (MK-2748-002 AM1)).] |
|
Eptinezumab
|
DB14040 |
[Eptinezumab is a fully humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Alder Biopharmaceuticals [A33105]. The agent is currently in clinical trials for preventing migraine attacks. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human calcitonin gene-related peptide (CGRP) [F94, A33105, A33106, A33108].] |
|
Balixafortide
|
DB15370 |
[Balixafortide is under investigation in clinical trial NCT03786094 (Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer).] |
|
Triglu-5-formyl-tetrahydrofolate
|
DB02067 |
|
|
Ethyl Isocyanide
|
DB03399 |
|
|
N7-Methyl-Formycin A
|
DB02066 |
|
|
N-(2-Flouro-Benzyl)-4-Sulfamoyl-Benzamide
|
DB02069 |
|
|
Uridine-Diphosphate-N-Acetylglucosamine
|
DB03397 |
|
|
Delta-Amino Valeric Acid
|
DB02068 |
|
|
Alpha-Ribazole-5'-Phosphate
|
DB02030 |
|
|
(13S)-13-METHYLDODECAHYDRO-1H-CYCLOPENTA[A]PHENANTHRENE-3,17(2H,4H)-DIONE
|
DB04693 |
|
|
N-Dimethyl-Lysine
|
DB03362 |
|
|
3-Acetylpyridine Adenine Dinucleotide
|
DB03363 |
[A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage. It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed)] |
|
2,6-anhydro-3-deoxy-3-fluoronononic acid
|
DB04694 |
|
|
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid
|
DB02032 |
|
